Cardiovascular and metabolic diseases continue to be the leading cause of death globally, accounting for 19 million deaths annually, and tremendous health and societal burden.  Despite the many therapies that have been developed, a significant unmet need persists. Over the last years, recent advances and breakthroughs in human genetics and disease biology understanding have highlighted new disease biology and targets that were unknown before. In addition, newer therapeutic modalities (e.g siRNAs, ASOs, cell therapies and gene silencing) are helping scientists address previously difficult to drug targets or provide long acting modulation. Roche is highly committed to making a contribution to areas of huge unmet need and societal burden through transformative science and expands its footprint in cardiovascular and metabolic diseases.

  • Uncontrolled hypertension

  • Obesity¬† (also in context of Diabetes)

  • MASH (metabolic dysfunction-associated steatohepatitis)

  • Myocardial infarction/ stroke secondary prevention

  • Cardiomyopathies

  • SPAF (stroke & systemic embolic prevention in atrial fibrillation)

If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.